A targeted program that allows all prescribers to access real-time data and track and compare their own performance with those of others can improve compliance with opioid prescribing guidelines.
The FDA has approved the supplemental Abbreviated New Drug Application (sANDA) for Orphengesic Forte.
From 2005 to 2016, skeletal muscle relaxant (SMR) use increased in the United States.
In 2015 to 2018, 10.7% of US adults aged 20 years or older used one or more prescription pain medications.
For patients with chronic low back pain, tanezumab 10 mg significantly improves pain and function.
Biota Biosciences announced the voluntary recall of CBD Complex, Curcumin Complex, and Cannabidiol + Curcumin Injectables due to the products being marketed without the approval of the FDA.
Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults ≥18 years old.
The FDA Advil Dual Action with Acetaminophen for the temporary relief of minor aches and pains due to arthritis and more.
Investigators explored concerns with regard to opioid prescribing in compliance with new regulations in a commentary piece.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.